Literature DB >> 30803294

Association Between Depression and Outcomes in Chinese Patients With Myocardial Infarction and Nonobstructive Coronary Arteries.

Xiao-Hong Gu1, Chao-Jie He2, Liang Shen2, Bin Han3.   

Abstract

Background Myocardial infarction with nonobstructive coronary arteries ( MINOCA ) occurs in ≈10% of all patients with myocardial infarction. Studies on effects of depression on MINOCA outcomes are lacking. Therefore, the aim of this study was to examine the association of depression with clinical outcomes in Chinese patients with MINOCA . Methods and Results We conducted a prospective cohort study of 633 participants with MINOCA and followed up for 3 years. End points were defined as all-cause mortality and cardiovascular events. Diagnosis of depression was ascertained using the psychiatric interview based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). During the follow-up period, all-cause death occurred in 93 individuals and cardiovascular events developed in 170 individuals. Kaplan-Meier curves showed a significant association of depression with all-cause mortality (log-rank P<0.001) and cardiovascular events (log-rank P<0.001). Multiple Cox regression identified the new diagnosis of depression as an independent prognostic factor for all-cause mortality as well as cardiovascular events (adjusted hazard ratio, 7.250; 95% CI, 4.735-11.100; P<0.001; and hazard ratio, 3.411; 95% CI , 2.490-4.674; P<0.001, respectively). Conclusions The new diagnosis of depression at the time of myocardial infarction is associated with increased risk of adverse clinical outcomes in patients with MINOCA.

Entities:  

Keywords:  cardiac disease; depression; outcome

Mesh:

Year:  2019        PMID: 30803294      PMCID: PMC6474919          DOI: 10.1161/JAHA.118.011180

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


Clinical Perspective

What Is New?

Depression is frequent in patients with myocardial infarction with nonobstructive coronary arteries. Depression is associated with increased risk of adverse outcomes in patients with myocardial infarction.

What Are the Clinical Implications?

These data support the notion that depression predicts adverse outcomes in patients with myocardial infarction. Future studies should evaluate whether depression treatment may improve clinical outcomes in patients with myocardial infarction with nonobstructive coronary arteries.

Introduction

Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a syndrome with many potential causes, characterized by clinical signs of myocardial infarction with normal or near‐normal coronary arteries on angiography.1, 2 MINOCA occurs in ≈10% of all those with acute myocardial infarction, and there is an overrepresentation of women compared with those with obstructive coronary arteris.3, 4, 5 Deaths are more likely to occur in women without obstructive coronary arteries.6 MINOCA is an exclusion diagnosis and may be the result of several potential causes, including plaque disruption, coronary artery spasm, thromboembolism, dissection, microvascular dysfunction, ischemic myocardial injury attributable to supply/demand mismatch, and myocarditis or Takotsubo cardiomyopathy.1, 7 Depression is common among patients with coronary heart disease, with prevalence ranging from 20% to 30%.8, 9 Accumulating evidence has shown that depression is associated with increased risk of adverse clinical outcomes in patients with myocardial infarction, independent of traditional cardiovascular risk factors.10, 11, 12, 13 Studies of effects of antidepressant medication on prognosis of patients with myocardial infarction have reached different conclusions.8, 14 Despite the high prevalence and poor clinical outcomes, mood and depression are often neglected and left untreated in this population.15, 16 Emerging studies on mental health in patients with MINOCA showed that depression is frequent, with prevalence similar to patients with coronary heart disease.17 To date, however, the association between depression and clinical outcomes has not been examined in patients with MINOCA. In addition, there are ethnic differences in depression among patients with coronary artery disease.18 No proper data on the prevalence of depression in Chinese patients with MINOCA exist. Therefore, we aimed to measure the prevalence of depression in Chinese patients with MINOCA and to determine the association between depression and clinical outcomes in patients with MINOCA.

Methods

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Setting and Participants

Patients with MINOCA were recruited consecutively from the Cardiology Department of the First Affiliated Hospital of Jiaxing University between October 2012 and November 2014. Inclusion criteria included the following: (1) Chinese ethnicity; (2) fulfilling the diagnostic criteria for acute myocardial infarction (International Classification of Diseases, 10th Revision [ICD‐10] codes I21‐I22); (3) coronary angiography performed during the hospitalization showing a stenosis of ≤50%; and (4) willingness to give written informed consent. Exclusion criteria were as follows: (1) patients with dementia or cognitive dysfunction; (2) patients with a history of depression or other psychiatric disorders (clinical diagnosis or previous treatment)19; (3) patients with previous myocardial infarction, severe chronic obstructive pulmonary, renal disease, atrial fibrillation, cancer, pulmonary embolism, and myocarditis; and (4) patients who died within 30 days after discharge. Informed consent was obtained from each patient before enrollment, and the study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of First Affiliated Hospital of Jiaxing University.

Baseline Characteristics

Baseline data were obtained from the patient record system and confirmed with each patient at enrollment. These data involved demographics, traditional cardiac risk factors, electrocardiographic changes on admission, and discharge medications with antiplatelets, β blockers, renin‐angiotensin‐aldosterone system inhibitors, and statins. Traditional risk factors were defined as presence of current smoking, hypertension, diabetes mellitus, and hyperlipidemia.

Assessment of Depression

Each patient was screened for depressive symptoms using the 17‐item Hamilton Depression Scale20 during or shortly after the admission for acute myocardial infarction. Patients with a 17‐item Hamilton Depression Scale score of ≥7 were given the Chinese version of the Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5), for diagnosis of depression. The structured psychiatric interview, which takes 30 to 45 minutes to complete, was performed by psychiatrists who were blind to the medical documents of patients.

Primary and Secondary End Points

Patients were followed up for 3 year from depression ascertainment. The primary end point in the current study was defined as all‐cause mortality. The secondary end points were cardiovascular events, consisting of cardiac death, recurrent myocardial infarction, heart failure, and ischemic stroke. End point ascertainment was performed on the same patient by 2 researchers who were blinded to admission depression status. Events were first determined by searching the patient record system. All patients were then contacted to examine whether any events had occurred outside the hospital; the data were collected from the discharge summary from the medical institution where the event occurred.

Statistical Analysis

The categorical variables are presented as percentage frequency and compared by χ2 test or Fisher's exact test. The continuous variables are presented as mean±SD or median (25th–75th percentile) and compared by Student t test or Mann‐Whitney U test. Kaplan‐Meier analyses were used to examine unadjusted outcomes (all‐cause mortality and cardiovascular events) between the depressed and nondepressed patients by the log‐rank statistic. Cox regression analyses were used to determine the associations between depression and outcomes by comparing the 2 patient groups after adjusting for the following: age, sex, traditional cardiac risk factors, electrocardiographic changes, and medications. Results were estimated as hazard ratios (HRs) with 95% CIs. A 2‐sided P<0.05 was considered statistically significant for all tests. All analyses were performed with SPSS 22.0 (SPSS Inc, Chicago, IL).

Results

Baseline Characteristics Stratified by Depression Status

Of 677 patients with MINOCA at baseline, 44 were excluded from this analysis: 3 with dementia, 2 with a history of depression, 5 with previous myocardial infarction, 6 with severe chronic obstructive pulmonary disease, 6 with renal disease, 5 with atrial fibrillation, 9 who refused to participate in the current study, and 8 who died within 30 days after discharge. Hence, the study cohort in the current study contained 633 patients with MINOCA. There were no significant differences in demographic and clinical characteristics between our cohort and those excluded. Of the 633 patients who formed the study sample, 166 (26.2%, 92 women) were diagnosed with depression and 422 were not. Only 32 depressed patients (19.2%) agreed to take an antidepressant medication with selective serotonin reuptake inhibitors; and the other 134 depressed patients (80.8%) chose to go to the psychiatric hospital to confirm the diagnosis of depression, which made it difficult for us to obtain the information about their medication. Patients with depression had higher all‐cause mortality (P=0.001) and cardiovascular events (P<0.001) compared with those without depression (Table 1). There were no significant differences between the 2 patient groups in sex, age, traditional cardiac risk factors, ST‐segment elevation on admission, and medications at discharge (Table 1).
Table 1

Baseline Characteristics of the Study Cohort Stratified by Depression

CharacteristicsNot Depressed (n=467)Depressed (n=167) P Value
Demographics
Age, mean±SD, y64.4±13.064.0±11.10.699
Female sex, n (%)287 (61.5)92 (55.4)0.173
Risk factors, n (%)
Current smoking90 (19.3)28 (16.9)0.494
Hypertension234 (50.1)84 (50.6)0.913
Diabetes mellitus85 (18.2)33 (19.9)0.633
Hyperlipidemia141 (30.2)54 (32.5)0.575
Electrocardiographic changes on admission, n (%)
ST‐segment elevation74 (15.8)26 (15.7)0.956
Medications at discharge, n (%)
Antiplatelets423 (90.6)153 (92.2)0.539
β Blockers387 (82.9)141 (82.9)0.538
RAAS inhibitors322 (69.0)107 (64.5)0.287
Statins389 (83.3)133 (80.1)0.355
Outcomes, n (%)
All‐cause mortality56 (12.0)37 (22.3)0.001
Cardiovascular events108 (23.1)62 (37.3)<0.001

RAAS indicates renin‐angiotensin‐aldosterone system.

Baseline Characteristics of the Study Cohort Stratified by Depression RAAS indicates renin‐angiotensin‐aldosterone system.

Association of Depression With MINOCA Outcomes

During the follow‐up of 3 years, all‐cause death occurred in 93 individuals and cardiovascular events developed in 170 individuals: 44 cardiac deaths, 51 recurrent myocardial infarctions, 46 heart failures, and 29 ischemic strokes. Kaplan‐Meier curves showed a significant association of depression status with all‐cause mortality (log‐rank P<0.001; Figure[A]) and cardiovascular events (log‐rank P<0.001; Figure[B]). In univariate Cox regression analyses, depression was significantly associated with increased risks of all‐cause mortality as well as cardiovascular events (HR, 8.573; 95% CI, 5.663–12.980; P<0.001; and HR, 3.970; 95% CI, 2.919–5.401; P<0.001, respectively). After adjusting for demographic and clinical variables in multiple Cox regression models, depression remained an independent prognostic factor for all‐cause mortality as well as cardiovascular events (HR, 7.250; 95% CI, 4.735–11.100; P<0.001; and HR, 3.411; 95% CI, 2.490–4.674; P<0.001, respectively) (Tables 2 and 3). Moreover, ST‐segment elevation and medications, including renin‐angiotensin‐aldosterone system inhibitors and statins, were significantly associated with clinical outcomes (Tables 2 and 3), agreeing with the findings of previous studies.
Figure 1

Cumulative event‐free survival (Kaplan‐Meier curves) for outcomes (all‐cause mortality [A] and cardiovascular events [B]) in patients with and without depression.

Table 2

Multiple Cox Regression of Variables Influencing All‐Cause Mortality

VariablesHR (95% CI) P Value
Age, y1.015 (0.997–1.034)0.099
Female sex1.236 (0.813–1.878)0.321
Current smoking0.700 (0.411–1.190)0.187
Hypertension1.079 (0.713–1.633)0.719
Diabetes mellitus1.290 (0.721–2.311)0.391
Hyperlipidemia0.981 (0.622–1.546)0.933
ST‐segment elevation5.643 (1.373–23.188)0.016
Antiplatelets0.903 (0.404–2.021)0.805
β Blockers0.809 (0.454–1.442)0.472
RAAS inhibitors0.472 (0.258–0.862)0.015
Statins0.398 (0.259–0.614)<0.001
Depression7.250 (4.735–11.100)<0.001

HR indicates hazard ratio; RAAS, renin‐angiotensin‐aldosterone system.

Table 3

Multiple Cox Regression of Variables Influencing Cardiovascular Events

VariablesHR (95% CI) P Value
Age, y1.007 (0.995–1.020)0.260
Female sex1.157 (0.852–1.573)0.350
Current smoking0.887 (0.597–1.317)0.551
Hypertension0.920 (0.677–1.249)0.592
Diabetes mellitus0.776 (0.537–1.121)0.177
Hyperlipidemia1.014 (0.725–1.418)0.935
ST‐segment elevation2.591 (1.348–4.979)0.004
Antiplatelets1.089 (0.642–1.847)0.753
β Blockers0.941 (0.617–1.435)0.777
RAAS inhibitors0.584 (0.393–0.869)0.008
Statins0.496 (0.360–0.681)<0.001
Depression3.411 (2.490–4.674)<0.001

HR indicates hazard ratio; RAAS, renin‐angiotensin‐aldosterone system.

Cumulative event‐free survival (Kaplan‐Meier curves) for outcomes (all‐cause mortality [A] and cardiovascular events [B]) in patients with and without depression. Multiple Cox Regression of Variables Influencing All‐Cause Mortality HR indicates hazard ratio; RAAS, renin‐angiotensin‐aldosterone system. Multiple Cox Regression of Variables Influencing Cardiovascular Events HR indicates hazard ratio; RAAS, renin‐angiotensin‐aldosterone system.

Discussion

To the best of our knowledge, this is the first study to measure the prevalence of depression in Chinese patients with MINOCA and determine the possible association of depression with clinical outcomes in patients with MINOCA. We observed that depression is common among Chinese patients with MINOCA, with prevalence similar to other populations.17 More important, our results demonstrated that depression increases the risks of all‐cause mortality and cardiovascular events in patients with MINOCA. The exact mechanisms for the association of depression with adverse clinical outcomes are unclear. Depression has been associated with increased catecholamine levels and might characterize individuals susceptible to Takotsubo cardiomyopathy.21, 22, 23 Moreover, a recent study has shown an important role of depression in coronary artery spasm.24 As mentioned earlier, Takotsubo cardiomyopathy and coronary artery spasm are common and potential pathogenetic mechanisms in MINOCA.1, 7 They may, therefore, be mediating mechanisms through which depression in this population can affect prognosis. In addition to physiological mechanisms, behavioral mechanisms may be involved in adverse clinical outcomes in patients with MINOCA. Depression may diminish an individual's adherence to medical treatment and rehabilitation programs.25, 26 Furthermore, depression is correlated with unhealthy behaviors, such as smoking, high‐fat diet, lack of physical exercise, and disruptions of social relationships.27, 28, 29 These unhealthy behaviors may be the result of psychological mechanisms related to depression. Therefore, the effect of depression on poor prognosis is likely the result of bio‐psycho‐social interaction. The current study design has some strengths. First, in the present study, diagnosis of depression was ascertained using the psychiatric interview based on the DSM‐5. Second, the well‐known confounders that have significant effects on MINOCA outcomes, such as ST‐segment elevation and medications, including renin‐angiotensin‐aldosterone system inhibitors and statins,8, 30 were all used for adjustment. Several limitations were observed in the current study. First, patients with previous myocardial infarction and atrial fibrillation were excluded, which may make us underestimate the incidence of MINOCA outcome events. Second, residual confounding may exist in the association with depression, such as marital status or socioeconomic status; however, we did not have the data on these variables. Third, patients in the study sample were enrolled from a single Cardiology Department at one hospital, thereby raising concerns on generalizations from its findings. Fourth, an unavoidable limitation is the exclusion of patients who refused to give written informed consent. We tried to minimize the potential bias by enrolling volunteers consecutively. Fifth, we did not assess other psychiatric comorbidities. Finally, we did not collect data on Takotsubo cardiomyopathy and structural heart disease, including significant valvular heart disease, cardiomyopathies, and left ventricular ejection fraction, because of most patients without intact information mentioned above, which might affect both the incidence of depression as well as mortality rates.

Conclusions

Depression is common among Chinese patients with MINOCA. More important, the new diagnosis of depression at the time of myocardial infarction is associated with increased risk of adverse clinical outcomes in patients with MINOCA. These results underscore the importance of monitoring depression in patients with MINOCA. Prospective interventional studies should be encouraged to determine whether depression treatment can actually improve clinical outcomes in this population.

Sources of Funding

This work was supported by the Medical and Health Research Foundation of Zhejiang Province (2017KY651).

Disclosures

None.
  31 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  A bifactor model of the Beck Depression Inventory and its association with medical prognosis after myocardial infarction.

Authors:  Ricardo de Miranda Azevedo; Annelieke M Roest; Robert M Carney; Johan Denollet; Kenneth E Freedland; Sherry L Grace; Seyed H Hosseini; Deirdre A Lane; Kapil Parakh; Louise Pilote; Peter de Jonge
Journal:  Health Psychol       Date:  2016-02-22       Impact factor: 4.267

3.  Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA).

Authors:  John F Beltrame
Journal:  J Intern Med       Date:  2012-10-11       Impact factor: 8.989

4.  Post-myocardial infarction depression: increased hospital admissions and reduced adoption of secondary prevention measures--a longitudinal study.

Authors:  Vicki Myers; Yariv Gerber; Yael Benyamini; Uri Goldbourt; Yaacov Drory
Journal:  J Psychosom Res       Date:  2011-10-20       Impact factor: 3.006

5.  Depressive symptom dimensions and cardiac prognosis following myocardial infarction: results from the ENRICHD clinical trial.

Authors:  S Bekke-Hansen; M Trockel; M M Burg; C Barr Taylor
Journal:  Psychol Med       Date:  2011-06-20       Impact factor: 7.723

6.  Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis.

Authors:  A Meijer; H J Conradi; E H Bos; M Anselmino; R M Carney; J Denollet; F Doyle; K E Freedland; S L Grace; S H Hosseini; D A Lane; L Pilote; K Parakh; C Rafanelli; H Sato; R P Steeds; C Welin; P de Jonge
Journal:  Br J Psychiatry       Date:  2013-08       Impact factor: 9.319

7.  Neurohumoral features of myocardial stunning due to sudden emotional stress.

Authors:  Ilan S Wittstein; David R Thiemann; Joao A C Lima; Kenneth L Baughman; Steven P Schulman; Gary Gerstenblith; Katherine C Wu; Jeffrey J Rade; Trinity J Bivalacqua; Hunter C Champion
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

8.  An item-level analysis of the Center for Epidemiologic Studies Depression Scale (CES-D) by race and ethnicity in patients with coronary artery disease.

Authors:  Carla Boutin-Foster
Journal:  Int J Geriatr Psychiatry       Date:  2008-10       Impact factor: 3.485

9.  Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease.

Authors:  Mary A Whooley; Peter de Jonge; Eric Vittinghoff; Christian Otte; Rudolf Moos; Robert M Carney; Sadia Ali; Sunaina Dowray; Beeya Na; Mitchell D Feldman; Nelson B Schiller; Warren S Browner
Journal:  JAMA       Date:  2008-11-26       Impact factor: 56.272

Review 10.  Impact of antidepressants use on risk of myocardial infarction: A systematic review and meta-analysis.

Authors:  Krishna Undela; Gurumurthy Parthasarathi; Sharon Sunny John
Journal:  Indian J Pharmacol       Date:  2015 May-Jun       Impact factor: 1.200

View more
  8 in total

1.  Association Between Depression and Outcomes in Chinese Patients With Myocardial Infarction and Nonobstructive Coronary Arteries.

Authors:  Xiao-Hong Gu; Chao-Jie He; Liang Shen; Bin Han
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

2.  Sleep Quality, Sleep Duration, and the Risk of Adverse Clinical Outcomes in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries.

Authors:  Chun-Yan Zhu; Hui-Lin Hu; Guan-Min Tang; Jing-Chao Sun; Hui-Xiu Zheng; Chang-Lin Zhai; Chao-Jie He
Journal:  Front Cardiovasc Med       Date:  2022-02-28

3.  Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries.

Authors:  Javier Lopez-Pais; Bárbara Izquierdo Coronel; Sergio Raposeiras-Roubín; Leyre Álvarez Rodriguez; Oscar Vedia; Manuel Almendro-Delia; Alessandro Sionis; Agustin C Martin-Garcia; Aitor Uribarri; Emilia Blanco; Irene Martín de Miguel; Emad Abu-Assi; David Galán Gil; Manuela Sestayo Fernández; Maria Jesús Espinosa Pascual; Rosa María Agra-Bermejo; Diego López Otero; Jose María García Acuña; Joaquín Jesús Alonso Martín; Jose Ramón Gonzalez-Juanatey; Miguel Ángel Perez de Juan Romero; Iván J Núñez-Gil
Journal:  Front Cardiovasc Med       Date:  2022-03-14

4.  Clinical Features and Long-Term Outcomes in Very Young Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries.

Authors:  Pablo Juan-Salvadores; Víctor Alfonso Jiménez Díaz; Ana Rodríguez González de Araujo; Cristina Iglesia Carreño; Alba Guitián González; Cesar Veiga Garcia; José Antonio Baz Alonso; Francisco Caamaño Isorna; Andrés Iñiguez Romo
Journal:  J Interv Cardiol       Date:  2022-07-30       Impact factor: 1.776

5.  Clinical characteristics and prognosis of myocardial infarction with non-obstructive coronary arteries: A prospective single-center study.

Authors:  Javier Lopez-Pais; Bárbara Izquierdo Coronel; David Galán Gil; Maria Jesús Espinosa Pascual; Blanca Alcón Durán; Carlos Gustavo Martinez Peredo; Carlos Moreno Vinués; Paula Awamleh García; Jose Ramón Gonzalez-Juanatey; Javier Muñiz García; Joaquín Jesús Alonso Martín
Journal:  Cardiol J       Date:  2020-11-03       Impact factor: 3.487

6.  Association between anxiety and clinical outcomes in Chinese patients with myocardial infarction in the absence of obstructive coronary artery disease.

Authors:  Chao-Jie He; Chun-Yan Zhu; Bin Han; Hai-Zhen Hu; Shi-Jun Wang; Chang-Lin Zhai; Hui-Lin Hu
Journal:  Clin Cardiol       Date:  2020-06-09       Impact factor: 2.882

7.  Association Between Obstructive Sleep Apnea-Hypopnea Syndrome and Outcomes in Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease.

Authors:  Chao-Jie He; Lin-Feng Cao; Chun-Yan Zhu; Xiao-Ce Dai; Yue-Yan Yu; Yu-Juan Zhu; Chang-Lin Zhai; Gang Qian; Hui-Lin Hu
Journal:  Front Cardiovasc Med       Date:  2020-10-23

8.  Anxiety, depression, and medication adherence in Chinese patients with myocardial infarction in the absence of obstructive coronary artery disease.

Authors:  Menglu Liu; Chao Deng; Ping Yuan; Jianyong Ma; Peng Yu; Jie Chen; Yujie Zhao; Xiao Liu
Journal:  Clin Cardiol       Date:  2020-10-26       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.